These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 26670245

  • 21. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
    Caine EA, Fuchs J, Das SC, Partidos CD, Osorio JE.
    Viruses; 2015 Nov 17; 7(11):5919-32. PubMed ID: 26593938
    [Abstract] [Full Text] [Related]

  • 22. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides.
    Li X, Mao C, Ma S, Wang X, Sun Z, Yi Y, Guo M, Shen X, Sun L, Bi S.
    Biochem Biophys Res Commun; 2009 Dec 25; 390(4):1126-8. PubMed ID: 19799860
    [Abstract] [Full Text] [Related]

  • 23. An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice.
    In HJ, Lim H, Lee JA, Kim HJ, Kim JW, Hyeon JY, Yeo SG, Lee JW, Yoo JS, Choi YK, Lee SW.
    PLoS One; 2017 Dec 25; 12(5):e0178259. PubMed ID: 28542556
    [Abstract] [Full Text] [Related]

  • 24. Is a multivalent hand, foot, and mouth disease vaccine feasible?
    Klein M, Chong P.
    Hum Vaccin Immunother; 2015 Dec 25; 11(11):2688-704. PubMed ID: 26009802
    [Abstract] [Full Text] [Related]

  • 25. Progress on the research and development of inactivated EV71 whole-virus vaccines.
    Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang JZ.
    Hum Vaccin Immunother; 2013 Aug 25; 9(8):1701-5. PubMed ID: 23744508
    [Abstract] [Full Text] [Related]

  • 26. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine.
    Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC.
    Expert Rev Vaccines; 2016 Jul 25; 15(7):803-13. PubMed ID: 27206811
    [Abstract] [Full Text] [Related]

  • 27. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
    Cai Y, Ku Z, Liu Q, Leng Q, Huang Z.
    Vaccine; 2014 May 01; 32(21):2406-12. PubMed ID: 24657161
    [Abstract] [Full Text] [Related]

  • 28. Development of antiviral agents toward enterovirus 71 infection.
    Pourianfar HR, Grollo L.
    J Microbiol Immunol Infect; 2015 Feb 01; 48(1):1-8. PubMed ID: 24560700
    [Abstract] [Full Text] [Related]

  • 29. Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys.
    In HJ, Lim H, Lee JA, Lee SR, Jin YB, Jeong KJ, Hyeon JY, Yoo JS, Lee JW, Choi YK, Lee SW.
    PLoS One; 2018 Feb 01; 13(10):e0202552. PubMed ID: 30278051
    [Abstract] [Full Text] [Related]

  • 30. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
    Lim H, In HJ, Lee JA, Sik Yoo J, Lee SW, Chung GT, Choi YK, Chung JK, Cho SJ, Lee JW.
    Vaccine; 2018 Jun 07; 36(24):3445-3452. PubMed ID: 29739716
    [Abstract] [Full Text] [Related]

  • 31. Inactivated enterovirus 71 with poly-γ-glutamic acid/Chitosan nano particles (PC NPs) induces high cellular and humoral immune responses in BALB/c mice.
    Pathinayake PS, Gayan Chathuranga WA, Lee HC, Chowdhury MYE, Sung MH, Lee JS, Kim CJ.
    Arch Virol; 2018 Aug 07; 163(8):2073-2083. PubMed ID: 29619599
    [Abstract] [Full Text] [Related]

  • 32. Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice.
    Imura A, Sudaka Y, Takashino A, Tamura K, Kobayashi K, Nagata N, Nishimura H, Mizuta K, Koike S.
    J Virol; 2020 Feb 28; 94(6):. PubMed ID: 31896594
    [Abstract] [Full Text] [Related]

  • 33. Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD).
    Bello AM, Roshorm YM.
    Biologicals; 2022 Sep 28; 79():1-9. PubMed ID: 36089444
    [Abstract] [Full Text] [Related]

  • 34. Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine.
    Wang SM, Liu CC.
    Expert Rev Anti Infect Ther; 2014 Apr 28; 12(4):447-56. PubMed ID: 24579906
    [Abstract] [Full Text] [Related]

  • 35. Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine.
    Han X, Ying XL, Zhou SL, Han T, Huang H, Jin Q, Yang F, Sun QY, Sun XX.
    Hum Vaccin Immunother; 2014 Apr 28; 10(8):2220-6. PubMed ID: 25424925
    [Abstract] [Full Text] [Related]

  • 36. Considerations for developing an immunization strategy with enterovirus 71 vaccine.
    Li L, Yin H, An Z, Feng Z.
    Vaccine; 2015 Feb 25; 33(9):1107-12. PubMed ID: 25444807
    [Abstract] [Full Text] [Related]

  • 37. [Mechanism of intravenous immunoglobulin therapy for severe hand-foot-mouth disease: a review].
    Cao R, Han J, Qin E, Qin C.
    Sheng Wu Gong Cheng Xue Bao; 2011 May 25; 27(5):712-6. PubMed ID: 21845837
    [Abstract] [Full Text] [Related]

  • 38. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys.
    Dong C, Wang J, Liu L, Zhao H, Shi H, Zhang Y, Jiang L, Li Q.
    Hum Vaccin; 2010 Dec 25; 6(12):1028-37. PubMed ID: 21150270
    [Abstract] [Full Text] [Related]

  • 39. An inactivated enterovirus 71 vaccine in healthy children.
    Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, Jiang L, Dong C, Che Y, Huang T, Jiang Z, Xie Z, Wang L, Liao Y, Liang Y, Nong Y, Liu J, Zhao H, Na R, Guo L, Pu J, Yang E, Sun L, Cui P, Shi H, Wang J, Li Q.
    N Engl J Med; 2014 Feb 27; 370(9):829-37. PubMed ID: 24571755
    [Abstract] [Full Text] [Related]

  • 40. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.
    Zhang C, Yang Y, Chi Y, Yin J, Yan L, Ku Z, Liu Q, Huang Z, Zhou D.
    Vaccine; 2015 Sep 22; 33(39):5087-94. PubMed ID: 26296491
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.